Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...